Corcept Therapeutics Shifts Gears as New Oncology Drug Lands Key Clinical Endorsement

Corcept Therapeutics transitions from a one-drug Cushing’s company to a multi-therapy enterprise, driven by Lifyorli’s ovarian cancer launch, rising costs, and promising pipeline data.

For years, Corcept Therapeutics’ fortunes rose and fell with a single Cushing’s syndrome drug. That era is ending. The company is now navigating a strategic transformation, propelled by the commercial launch of Lifyorli (relacorilant) for ovarian cancer and a broadening pipeline that reaches well beyond endocrinology.

The immediate catalyst for this shift is a crucial regulatory nod. Lifyorli has been incorporated into the treatment guidelines of the National Comprehensive Cancer Network. In the U.S., this recommendation acts as a powerful gateway, influencing physician prescribing habits and insurance reimbursement decisions. The move signals that Corcept is no longer a one-product story but is evolving into a multi-therapy enterprise with revenue streams from both endocrinology and oncology.

That evolution, however, comes with upfront costs. The company has been investing heavily in building out its marketing and sales infrastructure to support the oncology rollout. Operating expenses have climbed sharply as a result, squeezing near-term profitability. Management has acknowledged the drag but remains confident, recently raising its full-year revenue guidance. The path back to the black is expected by the second quarter, with the speed of adoption among oncologists being the critical variable.

The oncology strategy will face a major test later this year. At the end of May 2026, Corcept is slated to present data from the ROSELLA study at a medical conference. These phase 3 results will detail survival benefits from a combination therapy involving relacorilant in ovarian cancer. Positive findings could significantly bolster the drug’s acceptance among specialists and solidify its market position. Further down the pipeline, the company anticipates results from the BELLA study, which is evaluating a triple-combination regimen, before year-end. Longer-term, clinical readouts for cervical and pancreatic cancer could dramatically expand relacorilant’s addressable patient population.

Meanwhile, Corcept is shoring up its core endocrinology business. After grappling with distribution snags, the company has overhauled its pharmacy network, resolving supply bottlenecks for hypercortisolism treatments. This stabilization allows the firm to reliably meet rising demand and frees up resources for new ventures.

Beyond oncology, the company is laying groundwork in neurology and metabolic disease. A phase 3 study for amyotrophic lateral sclerosis is slated to begin in the second half of 2026, building on earlier phase 2 data that suggested a reduction in mortality risk. Additionally, results from the MONARCH study, focused on the metabolic disorder MASH, are expected toward the end of the year. This diversification is designed to reduce Corcept’s historical dependence on a single therapeutic area.

For now, the immediate focus is operational execution. The ability to navigate reimbursement hurdles and manage the transition to specialty pharmacies efficiently will largely determine the company’s financial performance over the coming quarters. The second quarter looms as a pivotal moment, when Corcept aims to return to profitability and demonstrate that its new multi-product model can deliver sustainable growth.